How much does a box of Ji San Dai (Bing Tong Sha) cost and buying guide

Epclusa (Epclusa), as an innovative oral antiviral drug, was carefully developed by Gilead Sciences and is designed to treat chronic hepatitis C virus (HCV) infection of all genotypes. Its core ingredients include Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). The former is a nucleotide polymerase inhibitor, and the latter is an NS5A inhibitor. The two work synergistically to effectively curb the replication and spread of hepatitis C virus in the body.

At present, Jisandai (Bingtonsha) has been launched in the Chinese market and has been successfully included in the scope of medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about more than 3,000 yuan. For specific prices and medical insurance reimbursement details, please consult your local hospital pharmacy for accurate information. It is worth noting that in foreign markets, the price of generic drugs in India and Bangladesh is relatively affordable, only a few hundred yuan, and the drug ingredients are basically the same as the domestic versions.

Jisandai (Bingtonsha) is suitable for the treatment of chronic hepatitis C of all 6 genotypes, especially for patients with liver cirrhosis or those who are unresponsive to other treatment options. For patients with decompensated cirrhosis, the combination of Bingtonsa) and ribavirin can significantly improve the therapeutic effect.

This drug is an oral preparation that only needs to be taken once a day, one tablet each time. It is recommended to take it at a fixed time to ensure the effectiveness of the drug. The standard treatment cycle is usually 12 weeks, but for some severe cases, the treatment time may need to be extended appropriately. Before treatment, a professional doctor should conduct a comprehensive assessment of the patient's condition and formulate a personalized treatment plan.

The clinical trial data of Jisanda (Bingtonsa) are encouraging, with its cure rate (SVR12) in patients infected with all genotypes of HCV , that is, the virus-undetected rate 12 weeks after the end of treatment) is as high as 95% or more. Common side effects such as headache, fatigue, nausea, etc. are mostly mild to moderate. For patients with severely impaired liver function, their liver function should be closely monitored and the treatment plan should be adjusted in a timely manner.

During treatment, patients should avoid taking proton pump inhibitors and other drugs that may affect the absorption of velpatasvir. At the same time, patients' viral load, liver function and related indicators need to be monitored regularly to ensure the safety and effectiveness of treatment. It is important to note that Jisandai (Bingtonsha) is not suitable for pregnant and lactating women. Before use, you should inform your doctor in detail about all the drugs you are using and your personal health conditions.